These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 8314306)
1. Changes in perfusion of mouse tumours after photodynamic therapy. van Geel IP; Oppelaar H; Oussoren YG; Stewart FA Int J Cancer; 1994 Jan; 56(2):224-8. PubMed ID: 8314306 [TBL] [Abstract][Full Text] [Related]
2. Treatment with the tumor necrosis factor-alpha-inducing drug 5,6-dimethylxanthenone-4-acetic acid enhances the antitumor activity of the photodynamic therapy of RIF-1 mouse tumors. Bellnier DA; Gollnick SO; Camacho SH; Greco WR; Cheney RT Cancer Res; 2003 Nov; 63(22):7584-90. PubMed ID: 14633671 [TBL] [Abstract][Full Text] [Related]
3. Mechanisms for optimising photodynamic therapy: second-generation photosensitisers in combination with mitomycin C. van Geel IP; Oppelaar H; Oussoren YG; Schuitmaker JJ; Stewart FA Br J Cancer; 1995 Aug; 72(2):344-50. PubMed ID: 7640216 [TBL] [Abstract][Full Text] [Related]
4. Cellular levels of photosensitisers in tumours: the role of proximity to the blood supply. Korbelik M; Krosl G Br J Cancer; 1994 Oct; 70(4):604-10. PubMed ID: 7917904 [TBL] [Abstract][Full Text] [Related]
5. Vascular perfusion and hypoxic areas in RIF-1 tumours after photodynamic therapy. van Geel IP; Oppelaar H; Rijken PF; Bernsen HJ; Hagemeier NE; van der Kogel AJ; Hodgkiss RJ; Stewart FA Br J Cancer; 1996 Feb; 73(3):288-93. PubMed ID: 8562332 [TBL] [Abstract][Full Text] [Related]
6. A green fluorescent protein-expressing murine tumour but not its wild-type counterpart is cured by photodynamic therapy. Castano AP; Liu Q; Hamblin MR Br J Cancer; 2006 Feb; 94(3):391-7. PubMed ID: 16421588 [TBL] [Abstract][Full Text] [Related]
7. The value of serum alpha-N-acetylgalactosaminidase measurement for the assessment of tumour response to radio- and photodynamic therapy. Korbelik M; Naraparaju VR; Yamamoto N Br J Cancer; 1998 Mar; 77(6):1009-14. PubMed ID: 9528849 [TBL] [Abstract][Full Text] [Related]
8. Irradiance controls photodynamic efficacy and tissue heating in experimental tumours: implication for interstitial PDT of locally advanced cancer. Shafirstein G; Bellnier DA; Oakley E; Hamilton S; Habitzruther M; Tworek L; Hutson A; Spernyak JA; Sexton S; Curtin L; Turowski SG; Arshad H; Henderson B Br J Cancer; 2018 Nov; 119(10):1191-1199. PubMed ID: 30353043 [TBL] [Abstract][Full Text] [Related]
9. Nitric oxide production by tumour tissue: impact on the response to photodynamic therapy. Korbelik M; Parkins CS; Shibuya H; Cecic I; Stratford MR; Chaplin DJ Br J Cancer; 2000 Jun; 82(11):1835-43. PubMed ID: 10839299 [TBL] [Abstract][Full Text] [Related]
10. In vivo resistance to photofrin-mediated photodynamic therapy in radiation-induced fibrosarcoma cells resistant to in vitro Photofrin-mediated photodynamic therapy. Adams K; Rainbow AJ; Wilson BC; Singh G J Photochem Photobiol B; 1999 Apr; 49(2-3):136-41. PubMed ID: 10392463 [TBL] [Abstract][Full Text] [Related]
11. In vivo relaxation time measurements on a murine tumor model--prolongation of T1 after photodynamic therapy. Liu YH; Hawk RM; Ramaprasad S Magn Reson Imaging; 1995; 13(2):251-8. PubMed ID: 7739367 [TBL] [Abstract][Full Text] [Related]
12. Does tumour uptake of Foscan determine PDT efficacy? Veenhuizen R; Oppelaar H; Ruevekamp M; Schellens J; Dalesio O; Stewart F Int J Cancer; 1997 Oct; 73(2):236-9. PubMed ID: 9335449 [TBL] [Abstract][Full Text] [Related]
13. Photodynamic therapy creates fluence rate-dependent gradients in the intratumoral spatial distribution of oxygen. Busch TM; Wileyto EP; Emanuele MJ; Del Piero F; Marconato L; Glatstein E; Koch CJ Cancer Res; 2002 Dec; 62(24):7273-9. PubMed ID: 12499269 [TBL] [Abstract][Full Text] [Related]
14. Reduction of tumour oxygenation during and after photodynamic therapy in vivo: effects of fluence rate. Sitnik TM; Hampton JA; Henderson BW Br J Cancer; 1998 May; 77(9):1386-94. PubMed ID: 9652753 [TBL] [Abstract][Full Text] [Related]
15. The characterization of blood flow changes in mouse tumor during Photofrin-based photodynamic therapy by using the color Doppler ultrasonography. Dubreta K; Ivankovic S; Lovrencic-Huzjan A; Bosnar-Puretic M; Stojkovic R; Jurin M Oncol Rep; 2009 Nov; 22(5):1253-7. PubMed ID: 19787247 [TBL] [Abstract][Full Text] [Related]
16. Expression of vascular endothelial growth factor in mouse tumours subjected to photodynamic therapy. Uehara M; Inokuchi T; Sano K; ZuoLin W Eur J Cancer; 2001 Nov; 37(16):2111-5. PubMed ID: 11597392 [TBL] [Abstract][Full Text] [Related]
17. Increased tumour dihydroceramide production after Photofrin-PDT alone and improved tumour response after the combination with the ceramide analogue LCL29. Evidence from mouse squamous cell carcinomas. Separovic D; Bielawski J; Pierce JS; Merchant S; Tarca AL; Ogretmen B; Korbelik M Br J Cancer; 2009 Feb; 100(4):626-32. PubMed ID: 19223911 [TBL] [Abstract][Full Text] [Related]
18. Photofrin accumulation in malignant and host cell populations of various tumours. Korbelik M; Krosl G Br J Cancer; 1996 Feb; 73(4):506-13. PubMed ID: 8595166 [TBL] [Abstract][Full Text] [Related]
19. Neutrophils as inflammatory and immune effectors in photodynamic therapy-treated mouse SCCVII tumours. Sun J; Cecic I; Parkins CS; Korbelik M Photochem Photobiol Sci; 2002 Sep; 1(9):690-5. PubMed ID: 12665307 [TBL] [Abstract][Full Text] [Related]
20. A Comparison of Dose Metrics to Predict Local Tumor Control for Photofrin-mediated Photodynamic Therapy. Qiu H; Kim MM; Penjweini R; Finlay JC; Busch TM; Wang T; Guo W; Cengel KA; Simone CB; Glatstein E; Zhu TC Photochem Photobiol; 2017 Jul; 93(4):1115-1122. PubMed ID: 28083883 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]